Analytical Data
-
Gene name
HLA-A*02:01&B2M&HER2(LIAHNQVRQV) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & HER2 (LIAHNQVRQV)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&LIAHNQVRQV
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research into the HLA-A*02:01/B2M/HER2 (LIAHNQVRQV) monomeric recombinant protein is anchored in the critical role of the human leukocyte antigen (HLA) system in immune recognition and response, particularly in cancer immunotherapy. HLA-A*02:01 is one of the most prevalent HLA class I alleles, presenting antigens to CD8+ T cells, and its ability to bind specific peptide sequences, such as the HER2-derived peptide LIAHNQVRQV, enhances its relevance in targeting malignancies expressing HER2. HER2 is a well-known oncoprotein implicated in several cancers, especially breast and gastric cancers, making it a prime target for immunotherapeutic strategies. By constructing a monomeric recombinant protein consisting of HLA-A*02:01 and β2-microglobulin (B2M) complexed with the HER2 peptide, researchers aim to investigate its structural and functional properties. This reconstituted form allows for detailed studies of T cell receptor (TCR) interactions, peptide binding affinity, and immune response activation. Understanding the characteristics and efficacy of this monomer is crucial for developing peptide-based vaccines and enhancing the activation of T cells against HER2-expressing tumors, paving the way for novel therapeutic approaches in cancer treatment.
